Carotid Artery Surgery Endarterectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid artery endarterectomy (CEA) is the surgical removal of atherosclerotic plaque from the internal carotid artery at the carotid bifurcation in the neck to restore normal blood flow to the brain and reduce the risk of ischaemic stroke. The operation is one of the most rigorously evaluated interventions in surgical medicine, with its benefit over medical therapy for symptomatic high-grade stenosis unequivocally demonstrated by the landmark NASCET and ECST randomised controlled trials enrolling over 6,000 patients. CEA reduces the five-year risk of ipsilateral stroke in symptomatic patients with 70–99% stenosis by approximately 48% compared to medical therapy alone.

The operation is performed under general or local anaesthesia (cervical block) with the patient supine and the head turned away from the operative side. A longitudinal incision is made along the anterior border of the sternocleidomastoid muscle, the carotid bifurcation is exposed, and vascular clamps are applied to the common, internal, and external carotid arteries. An arteriotomy is made along the common and internal carotid, the plaque is carefully dissected and removed under direct vision, and the artery is closed with either primary suture or a patch of saphenous vein, bovine pericardium, or PTFE to prevent restenosis. A temporary intraluminal shunt may be inserted during clamping to maintain cerebral perfusion and is guided by intraoperative monitoring.

The procedure takes approximately 60–90 minutes and requires one to two nights of hospital observation. Patients are discharged on antiplatelet therapy, statins, and antihypertensives. The benefit of early intervention — particularly within two weeks of a TIA or minor stroke — is a central principle of modern stroke prevention medicine.

The primary indication for carotid endarterectomy is symptomatic carotid stenosis — specifically, recently symptomatic internal carotid stenosis of 50–99% (NASCET criteria) ipsilateral to a transient ischaemic attack (TIA) or minor ischaemic stroke within the past six months, with maximum benefit when operated within two weeks of the index event. Amaurosis fugax (monocular visual transient ischaemia from ophthalmic artery emboli) arising from ipsilateral carotid plaque is an equivalent indication to hemispheric TIA. The timing criterion is critical: the absolute risk of recurrent disabling stroke within the first two weeks of a carotid TIA is 10–15%, and most of this risk is preventable by early endarterectomy.

Asymptomatic carotid stenosis above 60–70% is a secondary indication in patients with acceptable surgical risk and life expectancy above five years. The annual stroke risk in asymptomatic patients on modern optimal medical therapy is approximately 1%, which is lower than the ACAS and ACST trial era, making the benefit of surgery over medical therapy smaller and more dependent on individual patient features including plaque instability on imaging, silent ischaemic lesions on MRI brain, and contralateral carotid occlusion.

Ideal candidates for carotid endarterectomy are patients aged under 80 years with recently symptomatic ipsilateral stenosis above 50% (maximum benefit above 70%), modified Rankin Scale score of 3 or less indicating preserved functional independence, general anaesthetic fitness, and no recent major hemispheric infarction (which requires a four-to-six week waiting period due to haemorrhagic transformation risk). The perioperative stroke and death rate at the operating centre must be below 6% for symptomatic patients to justify intervention over medical therapy — centres should publish their own outcome data.

Contraindications include complete carotid occlusion (no lumen to endarterectomise), distal internal carotid disease extending intracranially, large disabling completed stroke (haemorrhagic transformation risk), contralateral occlusion with borderline collateral reserve (requires careful risk-benefit analysis), life expectancy below two years from comorbid disease, severe uncorrected cardiac disease increasing operative mortality above 6%, and anatomically high carotid bifurcation at or above C2 where surgical access is unsafe. Carotid stenting (CAS) is preferred for patients with hostile neck anatomy from prior surgery or radiation.

Standard carotid endarterectomy with patch closure — saphenous vein, bovine pericardial, or PTFE patch — is the most widely practised technique and the most evidence-supported, reducing restenosis rates compared to primary arterial closure. Eversion endarterectomy — transection of the internal carotid artery with eversion and removal of the plaque sleeve — is an alternative achieving equivalent outcomes and avoiding the need for patch material, with shorter clamp times at experienced centres. Both techniques can be performed under general or local (cervical block) anaesthesia; local anaesthesia enables continuous neurological assessment during clamping, potentially reducing shunt usage.

Intraoperative monitoring during carotid clamping includes transcranial Doppler (TCD) assessment of middle cerebral artery flow velocity, somatosensory evoked potentials (SSEPs), and near-infrared spectroscopy (NIRS) of cerebral oxygen saturation. A shunt is inserted if flow velocity falls below 15 cm/s, SSEP amplitude reduces by more than 50%, or NIRS saturation drops below 60%. These monitoring strategies allow selective rather than routine shunting, reducing the technical complexity of the procedure while protecting all at-risk patients. Carotid artery stenting (CAS) using self-expanding nitinol stents with distal embolic protection is the alternative catheter-based technique, discussed in the carotid endarterectomy vs. stenting comparison. Transcervical carotid artery stenting with flow reversal (TCAR) uses a cervical incision, sheath placement in the common carotid artery, and temporary reversal of carotid flow to filter emboli during stenting — a safer catheter-based alternative technique, discussed in the carotid endarterectomy vs. stenting comparison. Antiplatelet therapy is continued indefinitely post-procedure.

Carotid endarterectomy provides robust, durable protection against ipsilateral stroke in appropriately selected patients. In symptomatic patients with 70–99% stenosis, five-year absolute risk reduction in ipsilateral stroke or peri-operative death is approximately 17% (NASCET), translating to a number needed to treat of approximately six patients — an exceptionally high treatment efficiency for a surgical intervention. The benefit is maximised when surgery is performed within two weeks of the index TIA or stroke, and declines progressively with delayed intervention.

In asymptomatic patients with stenosis above 60%, the ACST trial demonstrated a five-year absolute risk reduction in stroke of approximately 5.4% compared to medical therapy. This benefit is smaller and accrues over a longer follow-up period. Modern meta-analyses incorporating current medical therapy suggest the benefit in asymptomatic patients may be modest with optimal current pharmacological management, but carefully selected patients with unstable plaques, silent ipsilateral ischaemic lesions, or contralateral disease continue to benefit. Long-term patency of the endarterectomised artery is excellent — restenosis above 50% occurs in approximately 5–10% at ten years, rarely causing recurrent symptoms.

The principal perioperative risk of carotid endarterectomy is stroke — either embolic (from plaque fragments or thrombus during dissection or clamping) or haemodynamic (from inadequate collateral perfusion during clamping) — occurring in approximately 1.5–3% of patients at experienced vascular surgery centres. Minor stroke with complete or near-complete recovery is more common than major disabling stroke. Death within 30 days from any cause occurs in approximately 0.5–1.5% at specialist centres. Cardiovascular events — myocardial infarction, cardiac death — account for 1–2% of adverse outcomes, reflecting the atherosclerotic coronary disease comorbidity of carotid disease patients.

Cranial nerve injury — hypoglossal nerve (tongue weakness, dysarthria), vagus nerve/recurrent laryngeal nerve (hoarseness), or mandibular branch of facial nerve (lower lip asymmetry) — occurs in 5–10% and is usually temporary, resolving within weeks to months; permanent injury occurs in below 1%. Wound haematoma — an expanding neck collection compressing the airway — affects 2–5% and may require urgent surgical evacuation under general anaesthesia. Cerebral hyperperfusion syndrome — ipsilateral headache, seizures, and focal deficit from vasodilatory breakthrough in chronically ischaemic hemispheres — occurs in approximately 1–3% after carotid endarterectomy and requires aggressive blood pressure management.

Post-operatively, patients are monitored in a high-dependency or surgical ward for 12–24 hours with neurological observations every 30 minutes, blood pressure monitoring, and neck inspection for haematoma. Blood pressure is managed actively — hypertension (above 180 systolic) increases haemorrhagic transformation risk; hypotension (below 100 systolic) risks hypoperfusion. Aspirin is resumed immediately post-operatively and maintained lifelong. Additional antiplatelet therapy (clopidogrel) is maintained for one to three months. Hospital discharge typically occurs within one to two days.

Driving is permitted after two to four weeks, depending on neurological recovery and national driving authority guidelines. Patients with perioperative neurological events may require longer restrictions. Duplex ultrasound surveillance of the operated carotid is performed at one month, six months, and annually thereafter to detect restenosis and monitor the contralateral artery. Statin therapy (atorvastatin 40–80 mg), antihypertensive medications targeting blood pressure below 130/80 mmHg, and lifestyle modifications (smoking cessation, Mediterranean diet, aerobic exercise 150 minutes per week) are lifelong priorities. Neurological and stroke physician follow-up continues for at least one year after the index event.

Carotid endarterectomy costs USD 20,000–50,000 in the United States including surgeon fees, anaesthesia, hospitalisation, and post-operative monitoring. UK NHS covers eligible patients; private CEA in the UK costs GBP 8,000–18,000. In India, JCI-accredited vascular surgery centres at Apollo Hospitals, Fortis, and Narayana Health perform CEA for USD 3,000–7,000 total — including pre-operative duplex and CTA imaging, surgical procedure, hospitalisation, and post-operative neurovascular assessment — representing a saving of over 85% versus US prices.

Thailand (Bumrungrad International, Bangkok) charges USD 8,000–15,000; Turkey (Acibadem, Florence Nightingale) USD 5,000–12,000; Poland USD 4,000–8,000. The short hospitalisation (one to two days) and rapid return to independence make carotid endarterectomy logistically straightforward for international patients travelling for elective intervention. Patients should ensure the centre has a dedicated vascular surgery service with specific experience in CEA, not just general surgery with occasional carotid cases, and access to post-operative neurological care.

Carotid artery stenting (CAS) is the principal procedural alternative to CEA, performed via a percutaneous transfemoral catheter approach under local anaesthesia. CAS is preferred for anatomically high-risk surgical candidates (prior neck surgery, radiation, contralateral cranial nerve palsy, hostile neck), patients with cardiac contraindications to general anaesthesia, and those with restenosis after prior CEA. The CREST trial demonstrated non-inferiority of CAS to CEA for overall stroke, MI, or death, but with a higher peri-procedural stroke rate for CAS in older patients, favouring CEA in patients above 70 years. Optimal medical therapy — statins, antiplatelets, blood pressure control, smoking cessation — is the definitive treatment for all patients and is the sole treatment for low-grade and many asymptomatic stenoses.